MABTAS 500 MG

About

MABTAS 500 MG is a monoclonal antibody, likely Rituximab, that targets the CD20 antigen found on the surface of B-lymphocytes. It is primarily used in the treatment of various B-cell non-Hodgkin lymphomas, chronic lymphocytic leukemia, and certain autoimmune diseases like rheumatoid arthritis and granulomatosis with polyangiitis. By binding to CD20, MABTAS initiates a cascade of immune responses, including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the depletion of CD20-positive B-cells.

This depletion helps to control the proliferation of malignant B-cells or reduce the autoimmune activity mediated by B-cells. It is administered intravenously under close medical supervision, often requiring premedication to mitigate infusion-related reactions, providing a targeted therapeutic approach for these complex conditions.

Uses

• Treatment of non-Hodgkin lymphoma.
• Management of chronic lymphocytic leukemia.
• Therapy for rheumatoid arthritis.
• Treatment of granulomatosis with polyangiitis.

Directions For Use

Administer as an intravenous infusion under the supervision of a healthcare professional. Premedication may be required to reduce infusion-related reactions.

Benefits

• Targets and depletes CD20-positive B-cells.
• Effective in various B-cell malignancies.
• Reduces disease activity in autoimmune conditions.
• Can induce remission in lymphoma.
• Improves symptoms in rheumatoid arthritis.
• Offers a targeted therapeutic approach.

Side Effects

• Infusion-related reactions (fever, chills, rash, hypotension).
• Nausea and vomiting.
• Fatigue.
• Headache.
• Peripheral edema.
• Neutropenia (low white blood cell count).
• Thrombocytopenia (low platelet count).
• Infections (bacterial, viral, fungal).
• Progressive multifocal leukoencephalopathy (PML) (rare but serious).
• Tumor lysis syndrome (rare).
• Cardiac arrhythmias.
• Bowel obstruction/perforation (rare).

Safety Measures

• Alcohol - No specific interaction with alcohol, but general health advice to limit intake during illness or treatment applies.
• Pregnancy - MABTAS is not recommended during pregnancy due to potential B-cell depletion in the fetus. Use effective contraception.
• Breastfeeding - It is unknown if MABTAS is excreted in human milk. Breastfeeding is not recommended during treatment and for a period after.
• Liver - No specific dose adjustment is typically required for liver impairment.
• Kidney - No specific dose adjustment is typically required for renal impairment.
• Lung - Rare but serious pulmonary events, including interstitial lung disease, can occur. Monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.